Transthyretin amyloid cardiomyopathy remains one of cardiology's most underdiagnosed and lethal conditions — a disease where misfolded proteins silently stiffen and ultimately destroy heart muscle. The emergence of RNA-targeting therapeutics has reshaped what's possible, and this large, rigorously designed Phase 3 trial may determine whether eplontersen becomes a new standard of care for a condition that was largely untreatable just a decade ago.

CARDIO-TTRansform is a randomized, double-blind, placebo-controlled trial evaluating eplontersen — an N-acetylgalactosamine-conjugated antisense oligonucleotide — administered subcutaneously at 45 mg every four weeks for up to 140 weeks. The drug targets transthyretin (TTR) messenger RNA in hepatocytes, suppressing production of the circulating protein before it can misfold and deposit in cardiac tissue. Eligible participants carry histologically confirmed amyloid deposits or demonstrate grade 2–3 cardiac uptake on scintigraphy, have New York Heart Association class I–III symptoms, and show interventricular septum thickness exceeding 12 millimeters. Crucially, TTR stabilizers such as tafamidis are permitted alongside the investigational drug, allowing a real-world-mirroring standard-of-care backdrop. The primary composite endpoint captures cardiovascular mortality plus recurrent clinical cardiovascular events, while secondary endpoints include six-minute walk distance and Kansas City Cardiomyopathy Questionnaire scores.

Eplontersen has already demonstrated TTR-lowering efficacy in hereditary TTR polyneuropathy (NEURO-TTRansform trial), where it achieved sustained reductions exceeding 80% in circulating TTR levels. Whether equivalent suppression translates into meaningful cardiac outcomes in the wild-type and hereditary cardiomyopathy population is the critical unresolved question. This trial is methodologically notable for permitting concurrent tafamidis use — a pragmatic choice that could complicate signal detection but strengthens generalizability. The 140-week duration is appropriately ambitious given the disease's slow progression. If positive, eplontersen would represent the first hepatocyte-targeted RNA therapy approved specifically for the cardiomyopathy phenotype, potentially complementing or supplanting stabilizer therapy. The trial's hierarchical endpoint structure also signals regulatory maturity in this space. This is a potentially paradigm-shifting study for a disease where prognosis remains grim despite current options.